Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for royalty pharma
Sweden gets into the Article 3 SPC referral game in AstraZeneca dapagliflozin case Sweden gets into the Article 3 SPC referral game in AstraZeneca dapagliflozin case Reviewed by Henry P Yang on Wednesday, March 01, 2023 Rating: 5
New SPC referral to the CJEU on the interpretation of Art 3(a) and (c) for combination products (Merck v Clonmel) New SPC referral to the CJEU on the interpretation of Art 3(a) and (c) for combination products (Merck v Clonmel) Reviewed by Dr Rose Hughes on Monday, March 07, 2022 Rating: 5
The SPC alphabet: Are combination product SPCs precluded by Article 3(a), (c) and/or (d)? The SPC alphabet: Are combination product SPCs precluded by Article 3(a), (c) and/or (d)? Reviewed by Dr Rose Hughes on Monday, December 13, 2021 Rating: 5
Intellectual Property Challenges in the Bio-Pharmaceutical Field Intellectual Property Challenges in the Bio-Pharmaceutical Field Reviewed by Mike Mireles on Wednesday, May 04, 2016 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.